Indicated for improving health concerns associated with low progesterone levels in women, including premenstrual syndrome, irregular menstrual cycles, polycystic ovarian syndrome, peri-menopause, hyperprolactinemia, insomnia and infertility Provides a highly concentrated 10:1 extract of Vitex agnus-castus with vitamin C and a mixed tocopherol blend, sourced from GMO free rapeseed oil, to support healthy progesterone levels Pyridoxal-5-phosphate (P-5-P), the biologically active form of vitamin B6, is added for the efficient conversion of 5-HTP into serotonin and the production of other neurotransmitters Progesterone is primarily responsible for thickening the uterine lining in order to prepare the female body for implantation of a fertilized egg, but it plays many other roles
There is real precedent for this thinking
Medically reviewed by Alan Lucks | MD , Alan Lucks MDPC Private Practice - New York on December 30th, 2025
Warner, B
Mild to moderate pain Protocol: BPC-157: 250mcg twice daily Duration: 4-8 weeks Method: Injectable near pain site or systemic Expected outcome: 40-60% pain reduction Improved function May be sufficient alone Severe or chronic pain Protocol: BPC-157: 500mcg twice daily TB-500: 5-10mg weekly loading for 4-6 weeks, then 2-5mg maintenance Duration: 12-16 weeks minimum Method: Injectable Expected outcome: 50-70% pain reduction Significant functional improvement Better quality of life Multiple pain sites or systemic pain Protocol: BPC-157: 250-500mcg twice daily (systemic injections - abdomen/thighs) TB-500: 5mg weekly Optional: KPV 500mcg daily if inflammation major factor Duration: 12-24 weeks Expected outcome: 40-60% overall pain reduction Improved multiple areas Better mobility Maintenance protocol After initial relief: BPC-157: 250mcg daily OR every other day TB-500: 2-5mg weekly OR biweekly Duration: Ongoing as needed Why maintenance: Prevents pain return Continues healing Safe long-term Use our peptide dosing guide , peptide dosage chart , and how to calculate peptide dosages
doi: 10.1002/pmic.201300508 58 Van den BosscheJBaardmanJOttoNAvan der VeldenSNeeleAEvan den BergSMet al
